Uncategorized Archives - Page 44 of 145

FridayNov 04, 2022 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently…

WednesdayNov 02, 2022 9:45 am

India Globalization Capital Inc. (NYSE American: IGC) Is ‘One to Watch’

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC based formulation on Alzheimer’s patients The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. India Globalization Capital (NYSE American: IGC), through subsidiary…

MondayOct 24, 2022 10:30 am

Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway

Ketamine used for decades in large doses for surgical anesthesia, low-dose treatments currently prescribed for pain relief, sedation, and treatment-resistant depression Silo’s time-released ketamine formulation SP-26 currently undergoing safety evaluation, study to uncover maximum tolerated dosing data for future trials SP-26 previously reported positive results in reducing neuropathic nerve pain Silo preparing FDA Pre-Investigational New Drug (“IND”) package for SP-26, intends to pursue 505(b)(2) regulatory pathway Ketamine was approved in the United States in 1970 and has been used extensively for surgical anesthesia. Since then, use of the drug in small doses has expanded considerably to treat pain and treatment-resistant…

TuesdayOct 18, 2022 9:45 am

Odyssey Health, Inc. (ODYY) Updates Progress of its Concussion Drug Development Program; Communicating with the FDA for permission to start phase II clinical trial of its PRV-002 Drug Candidate

Odyssey acquired IP and all rights to PRV-002, its lead drug candidate for the treatment of concussions, on March 1, 2021, and has since made notable progress in a strategic move to have the drug approved by the FDA Since the acquisition, the company has completed IND enabling studies and all cohorts for Phase I SAD and MAD clinical trials for its lead drug candidate In pre-clinical studies PRV-002 has demonstrated equivalent, if not superior neuroprotective effects compared to related neurosteroids, offering proof of reduced behavioral pathology associated with brain injury symptoms, easily crossing the blood-brain barrier to rapidly eliminate…

FridayOct 14, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate

Odyssey Health is a medical company developing unique, life-saving products that address unmet clinical needs such as concussion, which does not have an FDA-approved therapeutic The company has developed PRV-002, a neurosteroid for the treatment of concussion, and an intranasal delivery device that delivers the drug into the upper chamber of the nasal cavity for onward travel into the brain Odyssey’s just concluded Phase I clinical trial shows that PRV-002 is safe and well tolerated The findings from the study are likely to benefit the military as well as the NFL, given military personnel and players frequently suffer concussions In…

MondayOct 10, 2022 9:00 am

Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol

The concussion controversy surrounding Tua Tagovailoa has prompted both the NFL and the NFLPA to revisit the league’s concussion protocol in a move designed to enhance player safety In the wake of this controversy, Odyssey is emphasizing the potential value of its PRV-002 novel compound for the treatment of concussions and the benefit of the players According to a report published by Vox, there are approximately 0.41 concussions per NFL game in American football, with 9.3% of concussions involving the loss of consciousness and 2.4% resulting in hospitalizations With such cases, there is a need to revise the NFL’s concussion…

ThursdayOct 06, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs With concussion representing a high unmet need as there is currently no FDA-approved drug, Odyssey is developing a drug formulation, PRV-002, to be administered to concussed patients; the drug candidate is currently undergoing clinical evaluation In a recent announcement, the company reported the successful completion of its Phase I clinical trial, which showed that the drug was safe and well tolerated Odyssey is looking to present the findings of the Phase I study to the FDA and is also preparing…

WednesdayOct 05, 2022 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market

Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 million The biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the field Meanwhile, psychedelics are gaining increasing favour within the United States with Oregon set to begin allowing the supervised usage of psilocybin from 2023 onwards Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had successfully priced its fully underwritten initial public offering,…

TuesdayOct 04, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial

Odyssey successfully completed the second Cohort of its Phase I MAD clinical trial, proving the safety profile of its concussion pharmaceutical treatment, PRV-002 This study built on the success of Cohort I, where the drug was well tolerated and proved safe, with no severe adverse events reported The company’s Phase I Single Ascending Dose (“SAD”) cohorts of the clinical trial closed on July 12, 2022, proving the drug was safe and well tolerated. Results from this study were well received by the SRC, who also expressed their optimism for Odyssey’s completion of the MAD portion of its Phase I trial…

MondayOct 03, 2022 10:45 am

HeartBeam Inc. (NASDAQ: BEAT) Receives US Patent for Exclusive ECG Patch Monitor Designed to Detect Heart Issues

The USPTO issued a patent for BEAT’s 12-lead electrocardiogram (“ECG”) patch monitor for detection of ACS and cardiac arrhythmia HeartBeam has developed the only 3D-vector ECG platform for heart-attack detection anytime, anywhere BEAT’s patch technology could have a disruptive effect on the ECG patch market with its ischemia detection capability News about heart attacks and other life-threatening cardiovascular issues is alarming. Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States (https://ibn.fm/FN4BR), and recent reports suggest that COVID-19 may cause heart problems (https://ibn.fm/7QAky) and that the incidence of heart…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

India Globalization Capital Inc. (NYSE American: IGC) Is ‘One to Watch’

Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway

Odyssey Health, Inc. (ODYY) Updates Progress of its Concussion Drug Development Program; Communicating with the FDA for permission to start phase II clinical trial of its PRV-002 Drug Candidate

Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate

Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol

Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated

Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market

Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial

HeartBeam Inc. (NASDAQ: BEAT) Receives US Patent for Exclusive ECG Patch Monitor Designed to Detect Heart Issues

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search